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Background: Biofilms formed by Candida albicans are resistant towards most of the available antifungal drugs.
Therefore, infections associated with Candida biofilms are considered as a threat to immunocompromised patients.
Combinatorial drug therapy may be a good strategy to combat C. albicans biofilms.
Methods: Combinations of five antifungal drugs- fluconazole (FLC), voriconazole (VOR), caspofungin (CSP),
amphotericin B (AmB) and nystatin (NYT) with cyclosporine A (CSA) were tested in vitro against planktonic and
biofilm growth of C. albicans. Standard broth micro dilution method was used to study planktonic growth,
while biofilms were studied in an in vitro biofilm model. A chequerboard format was used to determine
fractional inhibitory concentration indices (FICI) of combination effects. Biofilm growth was analyzed using
XTT-metabolic assay.
Results: MICs of various antifungal drugs for planktonic growth of C. albicans were lowered in combination with
CSA by 2 to 16 fold. Activity against biofilm development with FIC indices of 0.26, 0.28, 0.31 and 0.25 indicated
synergistic interactions between FLC-CSA, VOR-CSA, CSP-CSA and AmB-CSA, respectively. Increase in efficacy of the
drugs FLC, VOR and CSP against mature biofilms after addition of 62.5 μg/ml of CSA was evident with FIC indices
0.06, 0.14 and 0.37, respectively.
Conclusions: The combinations with CSA resulted in increased susceptibility of biofilms to antifungal drugs.
Combination of antifungal drugs with CSA would be an effective prophylactic and therapeutic strategy against
biofilm associated C. albicans infections.
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SynergismBackground
Candida albicans continues to be the most common
fungal pathogen and a major cause of high morbidity and
mortality among immunocompromised patients [1-3].
Candida readily forms biofilms on host tissues and med-
ical devices implanted in the patient’s body [4]. Options
of the antifungal drugs available for the treatment of sys-
temic and invasive candidiasis are restricted to polyenes,
allylamines, azoles and echinocandin class of molecules
[5]. Side effects due to toxicity of the drugs and emer-
gence of drug resistant strains have put limitations on
the effective use of these drugs [5-7]. Moreover, biofilms
show dramatically different properties from their* Correspondence: prof.karuppayil@gmail.com
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reproduction in any medium, provided the orplanktonic counterparts, such as increased resistance to
antimicrobial agents, multiple drug resistance and toler-
ance to host defenses. Susceptibility studies have revealed
that biofilms formed by C. albicans may be up to 2000
times more resistant to antifungal drugs than the plank-
tonic cells [4,8,9]. In this scenario, there is a need for new
strategies to combat fungal infections, especially biofilm
associated infections. Efforts are being done to explore
the efficacy of combination therapy in the treatment of
infections that are refractory towards antifungal drugs
[10]. Combinations of antifungal drugs from different
classes are being studied against C. albicans. Combining
azoles with flucytosine was found to result in either indif-
ference or antagonism [11,12]. Also, combinations of
AmB, azoles and echinocandin with azoles/ polyenes did
not show significant antifungal activity [13]. Not manyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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drug combinations against biofilm growth of C. albicans
[14]. Interestingly, results of combination against plank-
tonic cells may not always match with that of the biofilm
forms. For example, combination of FLC and AmB has
synergistic effects on planktonic growth of C. albicans
but does not alter activity of AmB against biofilms
[15,16]. FLC with CSP have antagonistic effects against
biofilms, unlike its planktonic counterpart [16,17]. This
suggests the need for drug combination studies in biofilm
settings. Various drugs including inhibitors of multidrug
efflux transporters, antimicrobial agents, membrane ac-
tive compounds, are being screened for their combined
activity with known antifungal drugs [18]. It was found
that growth of planktonic cells of C. albicans is sensitive
to the calcineurine inhibitors FK 506 and cyclosporine A
in combination with fluconazole [17]. Calcineurine is a
Ca2+ - calmodulin activated protein phosphatase, which
plays an important role in multiple aspects of fungal
physiology including cation homeostasis, morphogenesis,
antifungal drug resistance and virulence. Recently, it was
revealed that C. albicans biofilms are resistant to FLC as
well as CSA, however significantly sensitive to combin-
ation of the two [19]. Surprisingly, efficacy of CSA in
combination with other antifungal drugs has not been
studied. In our systematic study, for the first time we
have analyzed the effects of CSA combination with five
antifungal drugs (which belong to three classes) FLC &
VOR (azoles), AmB & NYT (polyenes) and CSP (echino-
candins). Efficacy of these combinations against plank-
tonic and biofilm growth of C. albicans is discussed.
Methods
Cultures and antifungal agents
A standard strain of Candida albicans ATCC 90028 was
obtained from the Institute of Microbial Technology,
Chandigarh, India. Culture was maintained on yeast ex-
tract peptone dextrose (YPD) agar slants at 4 °C (All the
media components were purchased from HiMedia la-
boratories Pvt. Ltd. Mumbai, India). Antifungal agents,
Fluconazole (FLC) (Forcan, Cipla Ltd., India), Voricona-
zole (VOR) (Vonaz, United Biotech Pvt. Ltd., India),
Caspofungin (CSP) (Cancidas™, Merck & Co. Inc.,
USA), Amphotericin B (AmB) (Lyka Pharm. Pvt. Ltd.,
India), Nystatin (NYT) (HiMedia, Pvt. Ltd., India),
Cyclosporine A (CSA) (Sun Pharm. India Ltd., India)
were obtained from local market.
Medium and culture conditions
Activation of culture was done by inoculating a single
colony from YPD agar plate (yeast extract 1 %, peptone
2 %, dextrose 2 %, agar 2 %) into 50 ml YPD broth in a
250 ml conical flask. The flasks were incubated at 30 °C
at 100 rpm on an orbital shaking incubator for 24 h.Cells were harvested by centrifugation at 2000 × g and
washed thrice with 0.1 M phosphate buffer saline (PBS),
pH 7.4. Final cell number was adjusted to 1×107 cells/ml
and used for experiments.
Susceptibility of planktonic cells to antifungal drugs
The susceptibility study was carried out by the standard
broth micro dilution method, as per CLSI guidelines
[20]. Briefly, various concentrations of drugs in the range
0.5 μg/ml to 32 μg/ml for FLC, 0.0625 μg/ml to 8 μg/ml
for VOR, CSP and AmB, 0.125 μg/ml to 16 μg/ml for
NYT and 7.75 to 500 μg/ml for CSA, were prepared in
RPMI-1640 medium pH 7.0, (with L-glutamine, without
sodium bicarbonate, buffered with 165 mM MOPS).
(HiMedia laboratories Pvt. Ltd. Mumbai, India). Drugs
were used in water soluble forms; hence the stock solu-
tions were prepared freshly in RPMI medium. A series
of concentrations were prepared in the 96 well plates by
double dilution. Wells without drugs served as a control.
Inoculum of 1×103 cells/ml was added to each well and
the plates were incubated at 37 °C for 48 hours and read
spectrophotometrically at 620 nm using a microplate
reader (Multiskan EX, Thermo Electron Corp., USA).
The lowest concentration of the drugs which caused fifty
percentage reduction in the absorbance compared to
that of control, was considered as minimum inhibitory
concentration (MIC); except for AmB where >70 %
inhibition of growth was considered MIC endpoint.
Chequerboard format for determination of FICI
Dilutions of individual drugs and their different combi-
nations were prepared in a chequerboard format as per
standard methodology [18]. A two dimensional array of
serial concentrations of test compounds were used for
preparation of drug dilutions. 100 μl of cell suspension
was added to each well and the micro plates were incu-
bated at 35 °C. After 48 h of incubation, absorbance was
read using microplate reader at 620 nm. MIC for growth
was determined as the concentrations of antifungal
drugs where 50 % reduction in the absorbance compared
to that of control was obtained. FIC indices were cal-
culated with a little modification. The FICI model is
expressed as: ΣFIC = FICA + FICB. Where, FICA =
(MIC of drug A in combination / MIC of drug A
alone) FICB = (MIC of drug B in combination / MIC
of drug B alone) When the value of ΣFIC ≤ 0.5, it is
the synergism and when ΣFIC >4 it is known as the
antagonism. A ΣFIC >0.5 but ≤ 4 is considered as
indifference [21,22].
Biofilm formation and drug susceptibility
For biofilm formation, 100 μl of the cell suspension
(1×107 cells/ml in PBS) was added to each well of 96
well micro plates. Plates were incubated at 37 °C on an
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were washed with sterile PBS to remove non-adhered
cells and 200 μl of RPMI-1640 medium was added to
adhered cells. To carry out susceptibility of biofilm de-
velopment, medium containing various concentrations
of the drugs was added at the zero hour of biofilm
formation i.e. immediately after adhesion phase and
the plates were incubated at 37 °C for 48 hours, at
100 rpm in an orbital shaker. While, to analyze the
effects on mature biofilms, medium with a range of
drug concentrations was added to the 24 hour old
biofilms. The plates were further incubated for 48
hours at 37 °C [23]. Density of the cells survived in
biofilm forms was analyzed through metabolic activity
in XTT-formazan reduction assay.Biofilm quantitation by XTT assay
Biofilm formation was quantitated using XTT [i.e. 2, 3-bis
(2-methoxy-4-nitro-sulfophenyl)-2H-tetrazolium-5-carbox-
anilide] (Sigma-Aldrich, India) reduction assay [23]. Briefly,
XTT solution was prepared by mixing 1 mg/ml XTT salt in
PBS and stored at −20 °C. Prior to use, menadione solution
prepared in acetone (Sigma-Aldrich, India) was added to
XTT to a final concentration of 4 μM. The wells containing
biofilms were washed with PBS to remove non adhered
cells and incubated for 5 hours in 100 μl of XTT-
menadione solution in dark, at 37 °C at 100 rpm. The color
formation by water soluble formazan product was mea-
sured at 450 nm using a microplate reader (Multiskan EX,
Thermo Electron Corp., USA). Wells without biofilms
served as a blank.Results
Cyclosporine A is synergistic with antifungal drugs
against planktonic forms
Planktonic growth of C. albicans was susceptible to
different antifungal drugs at varying concentrations.
MICs of FLC, VOR, CSP, AmB and NYT were found
at 0.5 μg/ml, 0.125 μg/ml, 0.25 μg/ml, 0.5 μg/ml and
1 μg/ml, respectively (Table 1, Figure 1). CSA alone
showed significant (≥50 %) inhibition of planktonicTable 1 MICs of antifungals alone and in combination with C
Name of Drug Minimum Inhi
Planktonic cellsa Biof
Drug alone Drug + 62.5 μg/ml CSA Drug alone
FLC 0.5 0.031 512
VOR 0.125 0.031 2
CSP 0.25 0.063 0.5
AmB 0.5 0.5 0.5
NYT 1 0.25 3
a Measured in terms of absorbance of cell density b Measured in terms of percentagrowth of C. albicans at concentration of 250 μg/ml
(data not shown). Concentrations lower than MIC did
not affect C. albicans, and >80 % growth was seen in
presence of 62.5 and 125 μg/ml CSA (Figure 1). A signifi-
cant decrease in MICs of antifungal drugs was observed
when cells were treated in presence of 62.5 μg/ml of
CSA. For example, MIC of FLC in combination with
CSA was found to be 0.031 μg/ml i. e. sixteen times less
than that of fluconazole alone. FIC index for the com-
bination was calculated to be 0.24, which indicated that
combination is synergistic. In presence of 125 μg/ml of
CSA, fluconazole activity was increased by 64 times
(Figure 1A). VOR concentration required to inhibit
C. albicans in presence of 62.5 μg/ml CSA was four
times less than MIC of VOR alone (Figure 1B). FIC
index for this combination was calculated to be 0.37.
While, 125 μg/ml of CSA increased the fluconazole
activity by eight fold. Addition of 62.5 and 125 μg/ml
of CSA lowered MIC of CSP to 0.063 and 0.008 μg/ml,
respectively, showing 4 and 32 fold increase in suscepti-
bility of C. albicans (Figure 1C). This combination was
found highly synergistic with the FIC index of 0.24.
Combination of 62.5 μg/ml of CSA was not effective;
however AmB in presence of 125 μg/ml of CSA inhibited
the growth at a concentration 32 times lesser than MIC
of AmB alone (Figure 1D). In presence of 62.5 and
125 μg/ml CSA, MIC of NYT for C. albicans growth
was obtained at 0.25 and 0.031 μg/ml, respectively. Com-
bination of NYT and CSA was 4 to 32 times efficient
than that of NYT alone (Figure 1E).
Biofilm development was sensitive to antifungal-CSA
combinations
Biofilm development was found resistant to FLC and sig-
nificant inhibition was obtained only at very high con-
centration (i. e. 512 μg/ml). Also, VOR concentration
required to inhibit biofilm formation was 16 fold high
than the MIC for planktonic growth. CSA showed MIC
for biofilms at 500 μg/ml concentration, whereas 62.5
and 125 μg/ml did not have any effect on biofilm develop-
ment. FLC- CSA combination was found highly synergistic
against biofilm development. Addition of 62.5 μg/ml ofSA against C. albicans
bitory Concentration (μg/ml)
ilm developmentb Mature biofilmsb






ge RMA obtained in XTT assay.
Figure 1 Effect of antifungal drugs alone and in combination with Cyclosporine A, on planktonic forms of C. albicans, A) FLC- CSA; B)
VOR- CSA; C) CSP- CSA; D) AmB- CSA; E) NYT- CSA.
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achieved at 1 μg/ml (Table 1, Figure 2A). The FIC index
for the combination was 0.26. In combination with
62.5 μg/ml of CSA, MIC of VOR was brought down to the
0.063 μg/ml (Figure 2B), with the FIC index of 0.28 in-
dicating the synergism. While, addition of 125 μg/ml
CSA showed decrease in VOR MIC for biofilm devel-
opment i. e. at 0.016 μg/ml concentration. Inhibition ofFigure 2 Activity of five antifungal drugs alone and in combination w
Percentage of growth was analyzed by comparing relative metabolic activi
B) VOR- CSA; C) CSP- CSA; D) AmB- CSA; E) NYT- CSA.biofilm development was obtained at CSP concentration
of 0.5 μg/ml, while combination with 62.5 and 125 μg/
ml of CSA caused eight folds decrease in the MIC to
make it 0.063 μg/ml (Figure 2C). A synergistic inter-
action between these two drugs was evident with FICI
of 0.31. The combination with CSA resulted in six-
teen fold decrease in concentration of the AmB
required to inhibit biofilm development to give MIC atith Cyclosporine A, against biofilm development of C. albicans.
ty (RMA) obtained through XTT metabolic assay. A) FLC- CSA;
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gested synergism between AmB and CSA. Combining
NYT and CSA did not show any decrease in MIC of the
individual drug (Figure 2E), and the FIC index of 0.62
indicated indifference.
Cyclosporine A sensitizes mature biofilms to the various
antifungal drugs
Mature biofilms were completely resistant to FLC and
VOR. MIC was obtained at very high i.e. 1024 and
4 μg/ml concentrations of FLC and VOR, respectively.
FLC alone was ineffective against mature biofilms, but
when combined with 62.5 μg/ml of CSA, synergistic
activity (FICI of 0.06) significantly eradicated the bio-
films at concentrations as low as 2 μg/ml (Table 1;
Figure 3A). While, in presence of 125 μg/ml CSA,
MIC of FLC was 0.5 μg/ml. Addition of CSA sensitized
mature biofilms so that MIC of VOR was obtained at
0.061 μg/ml (Figure 3B). FIC index of 0.14 indicated
synergism in this combination. Although CSP alone
was effective in biofilm eradication, it required higher
concentration compared to that of planktonic cells. One
μg/ml of CSP was required to remove 50 % of biofilm.
Combination of CSP-CSA caused eight fold decrease
in the MIC to bring it at 0.125 μg/ml (Figure 3C). FIC
index for this synergistic drug interaction was calcu-
lated to be 0.25. AmB combination with CSA showed
indifference and MIC of CSA-AmB for 24 h old bio-
film was found unchanged compared to AmB alone
(Figure 3D). Addition of CSA did not alter the activity
of NYT against biofilms. FIC indices of 0.5 and 0.62Figure 3 Effect of antifungal drugs alone and in combination with Cy
growth was analyzed by comparing relative metabolic activity (RMA) obtain
B) VOR- CSA; C) CSP- CSA; D) AmB- CSA; E) NYT- CSA.for combinations of CSA with AmB and NYT, respect-
ively, indicated indifference in activity.
Discussion
Biofilm associated C. albicans infections among im-
munocompromised patients is a challenge to clinical
treatment [4,8]. Various studies reported that biofilms
formed by C. albicans are resistant to most of the com-
monly used antifungal drugs [10,14]. Various reasons
have been proposed to be responsible for the antifungal
resistance of C. albicans biofilms [4,8,9] including the
calcinurine mediated tolerance to the drugs [17]. It is
considered as a multi factorial phenomenon resulting
due to surface induced gene expression. Hence, combin-
ation of drugs with different mode of action may inhibit
multiple cellular targets and hence would be a good
strategy against biofilms. Combinatorial approach
against planktonic form of C. albicans has been studied
and was found promising; however, only limited studies
are available on biofilms [14,16,17]. Results obtained
with planktonic forms may not always work in biofilm
setup. Our study is of significance as CSA combination
with various antifungal drugs is studied in planktonic as
well as biofilm growth forms. Biofilm formation and ma-
ture biofilms were found completely resistant to the
azoles, FLC and VOR, while CSP, AmB and NYT
required high concentrations for preventive activity
against biofilms. Resistance to FLC and VOR exhibited
by early and late biofilms was totally reverted by the
addition of CSA and biofilms became several folds sensi-
tive. Combination of azoles with CSA can be developedclosporine A, on mature biofilms of C. albicans. Percentage of
ed through XTT metabolic assay. A) FLC- CSA;
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tolerance to the drugs CSP and AmB in developing bio-
films was reverted in presence of CSA, exhibiting low
MIC values of CSP and AmB. Lowered antifungal con-
centrations may be physiologically relevant during treat-
ment of biofilm associated infections. Addition of CSA
did not alter sensitivity of mature biofilms to AmB and
NYT. At 62.5 and 125 μg/ml, CSA did not have any ef-
fect on growth and viability of C. albicans. However, in
presence of it the MICs of antifungal drugs for plank-
tonic growth of C. albicans were significantly reduced,
indicating ability of CSA to act as a chemosensitizer. FIC
indices obtained, suggests high synergistic activity of
antifungal drugs with CSA. The usefulness of FLC and
CSA combinations against C. albicans planktonic and
biofilm forms are reported by various workers [17].
However, our study for the first time demonstrates the
potential of CSA against planktonic growth, biofilm for-
mation as well as mature biofilms in combination with
five antifungal drugs including FLC. Calcineurin is a
Ca2+-calmodulin- activated phosphatase which plays
important roles in various physiological functions of
C. albicans, including morphogenesis, cell wall biosyn-
thesis, antifungal drug resistance and virulence [17]. It
is reported to play a direct role in biofilm resistance
to fluconazole [17]. CSA is known as a calcineurine
inhibitor. Results obtained in this study suggests that
CSA mediated inhibition of biofilm specific mechan-
isms potentiates antifungals against drug resistant bio-
films. Increased susceptibility of planktonic cells and
reversal of drug resistance in biofilm growth forms
after addition of CSA indicates that calcineurine may
be playing important role in resistance to FLC, VOR
and CSP. However, the exact mechanisms behind CSA
mediated synergism with various antifungal drugs are not
understood [19]. Outcome of this in vitro study gives
insight into use of CSA- antifungal drug combinations
for treatment of biofilm associated Candida infections.
The antifungal drugs used in this study are also known
for their undesirable side effects in humans, as such, re-
duction in their effective dosages after combination with
CSA may be of wide interest. To confirm the utility of
these drug combinations in clinics, in vivo studies and
clinical trials are necessary.Conclusions
The results presented are the systematic information on
synergistic activity of CSA with various antifungal drugs
against planktonic and biofilm growth of C. albicans.
The study for the first time showed that, combination of
CSA sensitizes planktonic cells as well as drug resistant
biofilms to azoles, polyene and echinocandin antifungal
drugs. Further studies in this direction would give insightinto an effective strategy for the prophylaxis and treat-
ment of biofilm associated Candida infections.
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